First large-scale, multicenter proteogenomic analysis offers new insights into pediatric brain tumor biology


A comprehensive “proteogenomic” analysis of the proteins, genes, and RNA transcription involved in pediatric brain tumors has yielded a more complete understanding of these tumors, which are the leading cause of cancer-related deaths in children. The results could help physicians more accurately identify different types of tumors and methods for treating them.

Researchers from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and Children’s Brain Tumor Network (CBTN) collected and analyzed what’s known as genetic, genomic, and proteomic data from multiple types of brain tumors in children. The consortia consist of collaborators from the Icahn School of Medicine at Mount Sinai, National Cancer Institute, Fred Hutchinson Cancer Research Center, Children’s National Hospital, and Children’s Hospital of Philadelphia. The study, the first large-scale multicenter study focused on pediatric brain tumors, was available online in Cell on November 25.

“Pediatric cancers in general, and pediatric brain tumors in particular, have a relatively low mutational burden,” explains Pei Wang, PhD, lead corresponding author of the study and Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. “Thus, comprehensive characterization of the functional molecular biology of these tumors, including the proteogenomic analysis done in this study, is essential to better understand and treat pediatric brain tumors.”

This study is the first comprehensive survey of genomics (which aims to characterize DNA sequence alterations in a sample), transcriptomics (which aims to quantify copies of RNAs), global proteomics (which aims to identify and quantify proteins), and phosphoproteomics (which quantifies active proteins) across a large cohort of 218 tumor samples representing seven distinct types of brain tumors.

By characterizing biological themes that are shared among these different types of tumors, the study revealed new insights suggesting that current treatments being used for specific tumor types could be applied to others that share the same proteomic features. Specifically, the analyses revealed two distinct subgroups of pediatric craniopharyngioma, a type of pediatric brain tumor. One subgroup showed proteomic/phosphoproteomic characteristics that were strikingly similar to those of another type of tumor, known as “low-grade glioma (LGG) with BRAFV600E mutation.” This observation suggests that MEK/MAPK inhibitors, a type of chemotherapy that has been used against LGG-with-BRAFV600E-mutation tumors, might also help with this subset of pediatric craniopharyngiomas, which currently has no robust chemotherapeutic options.

“The driver of this joint study has been a commitment to data-sharing and open science. Coming together has given both CPTAC and CBTN an opportunity to expand our available resources for answering critically important biological questions. Harnessing the collective expertise across these consortia enables us to better understand the mechanisms of pediatric tumors, improve the process of target protein identification, and potentially improve cancer treatments,” said Adam Resnick, PhD, contributing researcher, Scientific Co-Chair for CBTN, and Director of the Center for Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia.

By leveraging the rich clinical outcome data of this cohort, the research team also identified new prognostic biomarkers for a type of tumor known as high-grade glioma (HGG). When HGG tumors have a genetic mutation known as a H3K27M mutation, they tend to be very aggressive and the patients have relatively short survival time. However, in those without the mutation, this study suggests that the abundance of proteins named IDH1 and IDH2 in the tumor tissues could help to identify which tumors with the non-mutated H3K27M gene may be less aggressive.

“Integration of the clinical, proteomic, and genetic data generated in this study allows us to construct a more comprehensive model of brain tumor biology, which will lead to more targeted treatments,” said Brian Rood, MD, contributing researcher, Executive Co-Chair for CBTN, and Medical Director of the Brain Tumor Institute at Children’s National Hospital.

The data analysis also showed key biological differences in samples from primary and recurrent tumors from the same patients, indicating the need for independent assessment and therapeutic decisions for these tumors.

“The current study is the first to reveal in pediatric brain tumors the power of proteins to better determine which patient might benefit from a given therapy, and our validation studies using targeted proteomics provide a platform for clinical implementation of the findings” said co-author Amanda Paulovich, MD, PhD, Aven Foundation Endowed Chair and professor in the Clinical Research Division at Fred Hutchinson Cancer Research Center. “As this work moves further along toward clinical validation, I hope it brings comfort to patients and their families who have suffered from this terrible disease.”

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

Maximizing Biorepositories for Research & Drug Discovery, New UpComing Webinar Hosted by Xtalks


biobanks face a variety of challenges in meeting the different interests and unique needs of their collaborators and partners in order to support a growing number of research studies

Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and challenges facing biorepositories and biobanks around the world seeking to maximize their resources for research and drug discovery. Whether the repository contains a small collection of samples or is a large-scale national or international repository, biobanking will continue to play a key role in accelerating the discovery and development of new drugs, as these efforts require access to a larger array of biological samples. At the same time, biobanks face a variety of challenges in meeting the different interests and unique needs of their collaborators and partners in order to support a growing number of research studies. Maximizing utility and sustainability are critical for the long-term success of biorepositories and biobanks.

This webinar will explore the enormous innovative potential for biobanks and biorepositories to support translational research using a variety of bio-sample types (tissue samples, tumor cells, DNA, RNA, blood samples) collected from population-based and/or disease-specific groups of individuals.

Join Professor Stephen Sawcer, University of Cambridge, Dept. of Clinical Neurosciences; Samantha Hutten, Staff Scientist, Michael J Fox Foundation for Parkinson’s Disease Research (MJFF); Gordon R. Bernard, MD, Executive Vice President for Research and Chief Research Officer, Vanderbilt University Medical Center (VUMC); Professor Maeve Lowery, Trinity College Dublin and Consultant Medical Oncologist, St. James Hospital; and and David Kavanagh, PhD, Director of Clinical Partnerships, Genuity Science in a live webinar on Tuesday, December 15, 2020 at 10am EST (3pm GMT/UK).

For more information, or to register for this event, visit Maximizing Biorepositories for Research & Drug Discovery.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Sydney Perelmutter

Tel: +1 (416) 977-6555 x 352

Email: sperelmutter@xtalks.com

Share article on social media or email:

Is this the end of toothpaste as we know it?


miBrite ChewPaste - Natural Toothpaste Tablets

miBrite ChewPaste – Natural Toothpaste Tablets

“ChewPaste is by far the best toothpaste tablet available. It’s important that the tablets be completely non-toxic and safe to eat, so they are made with medical-grade hydroxyapatite for remineralization instead of fluoride,” says Dr. Martin Giniger, Ph.D, DMD

For the second week in a row, miBrite, the brand that sparks confidence and smiles, smashes all records and announces another paradigm-shifting platform toothpaste tablet technology: ChewPaste. The first in a series of tablets features an all-natural toothpaste, good for the environment, and uses medical-grade hydroxyapatite to remineralize teeth.

Toothpaste tablets have become popular recently due to the environmental benefits that tablets provide over traditional toothpaste. Regular toothpaste contains over 80% of its weight in humectants and water. The humectants added to toothpaste such as glycerin, sorbitol, and propylene glycol are added to toothpaste to prevent the toothpaste from drying up and becoming crumbling sand (silica).

In addition to these liquids added into toothpaste that increases the weight and volume, liquids make it challenging to add many beneficial ingredients to the formulation since water will eventually break down the ingredient’s structure and make the ingredient no longer effective.

miBrite ChewPaste has been in development for years and is the innovation of the world’s top oral care researcher and product formulator, Dr. Martin Giniger, Ph.D., DMD. Dr. Giniger has a Ph.D. in biochemistry and has worked with many large pharmaceutical companies on developing new drugs. This experience has guided the development of miBrite ChewPaste to result in a soft-to-chew tablet which can deliver beneficial ingredients.

“We spent a great deal of time on the formulation of miBrite ChewPaste so that it would provide a better experience than traditional toothpaste and not only be a more environmentally conscious alternative,” says Dr. Giniger, adding, “ChewPaste is by far the best toothpaste tablet available. It’s important that the tablets be completely non-toxic and safe to eat, so they are made with medical-grade hydroxyapatite for remineralization instead of fluoride.”

Besides not containing any added liquids to miBrite ChewPaste, they are also sold in recycled and recyclable and reusable metal tins and use recycled paper for the outside box. miBrite ChewPaste is available in two different sizes: a 30 day supply (60 ChewPaste tablets) and a 90 day supply (180 tablets).

For more information, visit miBrite’s website: http://www.mibrite.com

About Smash Labs, LLC and miBrite

Smash Labs, LLC is a multi-faceted oral care product innovation international firm based in Boca Raton, Florida, and Amsterdam, The Netherlands. Dr. Martin Giniger, Ph.D., DMD heads the company as Smash Lab’s Chief Scientist and works together with Oral Care R&D formulator Matt Spaid. Smash Labs works closely with companies worldwide and helps them formulate the products of their dreams. For more information, visit http://www.smash-labs.com and http://www.mibrite.com

###

Share article on social media or email:

What Healthcare Needs from the New Administration & What It Will Probably Get – Industry Analysis by Loyale Healthcare


A new presidential administration will likely lead to some important changes for hospitals and health systems in the U.S.

Most healthcare executives now agree that consumerism will have a significant influence on their longer-term success. That will be especially true if the President-elect implements policies that broaden coverage, improve transparency and promote competition. – Kevin Fleming, CEO, Loyale Healthcare

We have written extensively on the issues facing healthcare executives, leading up to and in the midst of the COVID-19 pandemic. By focusing on the financial implications associated with a more consumer-driven, digitally enabled healthcare marketplace, we have endeavored to help healthcare executives recognize, and begin to correct, one of the industry’s most acute and persistent deficiencies – the patient’s financial experience. The current administration has pursued the creation of a more consumer-friendly industry. And, although the new administration will initially be preoccupied with COVID-19, it will pursue consumer-centered healthcare even more vigorously.

Healthcare figured prominently in Joe Biden’s campaign for the presidency from the outset. The pandemic has moved it to the forefront. Suddenly, earlier plans for expanded coverage, improved affordability and the expansion of Medicaid have taken a back seat as the new administration shifts its focus to COVID-19. The president-elect has named an elite panel of thirteen health experts to his Transition COVID-19 Advisory Board. Co-chaired by former Surgeon General Vivek Murthy, former Food & Drug Administrator David Kessler and Dr. Marcella Nunez-Smith, an associate professor of medicine and epidemiology at Yale.

Naturally, tackling the immediate threat to public health will occupy the incoming administration’s healthcare related activities. But with the promise of a COVID-19 vaccine from at least three of the several companies developing them, it’s now possible to envision the end of the health emergency. Looking beyond the execution of a comprehensive virus control and vaccine production/distribution strategy, we can begin to piece together the likely longer-term impacts of the administration’s healthcare agenda. All in all, according to a recent report published by PwC Health Research Institute (HRI),“healthcare executives can expect an administration with an expansionary agenda, looking to patch gaps in coverage for Americans and scrutinize proposed healthcare mergers.”

Although the PwC research report warns healthcare executives to plan for the possibility of the U.S. Supreme Court striking down the Affordable Care Act, that possibility seems unlikely now in light of the skepticism voiced by some conservative justices. If the ACA survives, the report suggests, healthcare organizations should “prepare for the possibility that millions more Americans could gain insurance under Biden.”

Listing several of the more prominent initiatives on the President-elect’s healthcare agenda, PwC rates the probability of success for each. Now that we know the new administration will have a smaller majority in the U.S. House of Representatives and faces the possibility of a continued minority position in the Senate (depending on the outcome of January runoffs for two senate seats in Georgia), political realities make it highly unlikely that some of the new administration’s bolder initiatives, like a public option, will ever succeed.

Of the initiatives that remain, three stand out because of their relatively high probability of success and their potential impact on healthcare providers. These are:


  • Increase premium tax credits for families to afford more generous plans – high probability with positive outcomes for providers
  • Stop surprise medical billing – moderate probability with positive or negative impacts for providers
  • Limit market concentration across healthcare systems – moderate probability with largely negative impacts on providers

These and the other healthcare agenda items listed in their report signal what PwC’s HRI calls the “New Health Economy, a healthcare system that revolves around consumers and is more digital, virtual, value-based, portable and open to new players from outside the industry and focused on wellness and prevention.” Noting that the COVID-19 pandemic has accelerated some of these trends, researchers foresee disproportionate gains for the providers that have, “invested in capabilities for growth toward the New Health Economy.”

As one might expect, healthcare providers have their own feelings about the new administration’s healthcare agenda. In an article published by HealthcareDive titled, “5 issues hospitals want Biden to tackle in his first 100 days,” the story’s authors cite the responses of numerous hospital leaders when asked about the most important items they want the president-elect to address during the earliest days of the new administration. In several fundamental ways, the executives’ hopes and the incoming government’s objectives align. The executive list includes:

1.    Pandemic response, continued relief – Support to assist providers in their response to the pandemic, including actions to cure supply chain issues and provide for additional financial funding.

2.    Bolstering healthcare coverage – Greater access to coverage to encourage patients to seek care and reduce instances of non-reimbursement or bad debt (particularly important now, when millions of Americans have lost employer-provided coverage due to COVID-related job losses).

3.    Increased access to Medicaid – Rolling back actions that have “restricted access to the safety net coverage or threatened the integrity of the program, which covers 75.5 million people and has seen enrollment skyrocket in the coronavirus recession.”

4.    (Relief from) reimbursement challenges – Reverse policies that have cut back on funding for facilities serving a large proportion of low-income or vulnerable patients.” This includes “cuts to outpatient clinic visits and Part B drug payments to hospitals in the 340B drug pricing program.”

5.    (Support for) telehealth – A continuation of policies that removed barriers to virtual care delivered virtually over digital channels. To that end, systems are “going to push to make the telehealth waivers that were enacted as part of the public health crisis permanent.”

Although it now seems certain that any follow up to the CARES Act’s initial round of federal stimulus for healthcare will fall to the incoming administration, the handwriting is on the wall. The current administration has pursued rules mandating price transparency to create “a competitive environment, where providers can compete for patients on the basis of cost and quality, that they are incentivized to innovate, to drive value in the system.” It seems certain that the incoming administration will pursue these goals even more vigorously.

Most healthcare executives now agree that consumerism will have a significant – if not defining – influence on their longer-term operating success. That will be especially true if the President-elect succeeds in implementing policies that broaden coverage, improve price transparency and promote provider competition. In an article we published in July titled, “COVID-19 and the Growing Demand for Healthcare Transparency,” we pointed out that “Before the COVID-19 public health crisis brought about an operational and financial crisis for many of America’s healthcare providers, a critical transformation was already underway for the industry.”

We’re confident that the incoming administration of President-elect Biden will bring critical attention to the challenges facing healthcare and America as we look to conquer the coronavirus and get back to normal. We’re just as confident about the industry’s accelerated entry into the New Health Economy and the new demands for more patient-centered experiences in every dimension of care – especially the financial dimension. At Loyale, we’re committed to remaining at the forefront of healthcare’s financial transformation.

Kevin Fleming is the CEO of Loyale Healthcare

About Loyale

Loyale Patient Financial Manager™ is a comprehensive patient financial engagement technology platform leveraging a suite of configurable solution components including predictive analytics, intelligent workflows, multiple patient financing vehicles, communications, payments, digital front doors and other key capabilities.

Loyale Healthcare is committed to a mission of turning patient responsibility into lasting loyalty for its healthcare provider customers. Based in Lafayette, California, Loyale and its leadership team bring 27 years of expertise delivering leading financial engagement solutions for complex business environments. Loyale currently serves approximately 12,000 healthcare providers across 48 states. Loyale is proud to have an enterprise-level strategic partnership with Parallon which includes the deployment of Loyale’s industry leading technology at all HCA hospitals and Physician Groups.

Share article on social media or email:

ChicExecs Donates to Susan G. Komen Foundation For Its Holiday Give Back Campaign


News Image

“We are passionate about giving back, especially during the holidays, to organizations we believe in,” added Kailynn Bowling, Co-Founder and Co-President of ChicExecs. “For us, there is no greater gift.”

ChicExecs Retail Marketing Agency is giving back this holiday season by donating to the Susan G. Komen Foundation in honor of its director of retail strategy, Nichole Evans, and her fight against breast cancer.

“It hits close to home because a family member has had breast cancer and overcame and we’ve watched our beloved team member and friend battle this devastating disease with courage and determination this year,” said Nikki Carlson, Co-Founder and Co-President of ChicExecs.

The Susan G. Komen Foundation addresses breast cancer in research, community health, global outreach, and public policy initiatives in order to make the biggest impact. According to the organization, an estimated 276,480 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S. in 2020 alone, along with 48,530 new cases of non-invasive breast cancer.⁣

“We are passionate about giving back, especially during the holidays, to organizations we believe in,” added Kailynn Bowling, Co-Founder and Co-President of ChicExecs. “For us, there is no greater gift.”

ChicExecs has contributed 10 percent of its proceeds from October in honor of Nichole and in recognition of breast cancer awareness month. The agency will continue to focus its charitable efforts to support the organization during the holidays and beyond.

To make a donation, please visit https://www.komen.org/how-to-help/donate/. For more information on ChicExecs and its services, go to https://chicexecs.com.

About ChicExecs: Based in San Marcos, California, ChicExecs Retail Marketing Agency is an award-winning firm founded by Nikki Carlson and Kailynn Bowling, encompassing their backgrounds in marketing, PR, business management, retail, and sales. By creating a cohesive strategy for brands with PR, Social Media, and Retail Strategy, the team of more than 60 employees develops innovative ways to generate retail sell-through and brand awareness on both regional and national levels. They know what it takes to turn a napkin idea into a household name.

Thresa Vinson

Senior Account Coordinator

ChicExecs Brand Strategy

820 Los Vallecitos Blvd Ste A-C

San Marcos, CA 92069

T (831) 251-1813

http://www.chicexecs.com

thresa@teamchicexecs.com

We would love your feedback! Click HERE to share

**Bronze 2019 and 2020 Stevie Winner for Women in Business**

**Voted one of the Best Corporate Cultures in America by Entrepreneur Magazine!**

Share article on social media or email:

Selecting the Fast Path in Diagnostics Manufacturing Without Sacrificing Performance, Upcoming Webinar Hosted by Xtalks


Speed to manufacturing launch is key for market share.

Before the advent of COVID-19, medical professionals reported running over 2 billion rapid diagnostic tests globally per year. Even in the pre-COVID era, the need to have speed to market in manufacturing with each new diagnostic technology was essential for diagnostic supply companies to ensure market share and supply chain continuity.

With the advent of SARS-CoV-2, the virus that causes COVID-19, public health officials anticipate the need for as many as 300 million tests per month in each the US and EU, increasing demand for diagnostic tests by a factor of ten over the coming years. With such demands, launching new technologies and products is even more urgent. The need for speed in manufacturing launch and efficiency with robust processing in production are critical components in bringing diagnostic tests, whether for COVID-19 or other health conditions, to market promptly and meet the supply chain demands. While most product launches use new, novel or updated technologies with unique configurations, the key aspects of manufacturing remain the same.

Speed to manufacturing launch is key for market share. Speed and efficiency, once in production, are key for supply and continued inventory. However, merely going fast does not mean just using faster equipment or getting the right supplier. In this webinar, the featured speaker will discuss how design, manufacturing strategy, and key technology partners are the cornerstone of achieving accelerated launch of diagnostic products and maintaining the production efficiency, quality and delivery that the market both needs and desires.

Join David Wolgemuth, Molding & Manufacturing Technology Specialist, Phillips-Medisize, in a live webinar on Friday, December 11, 2020 at 1pm EST.

For more information, or to register for this event, visit Selecting the Fast Path in Diagnostics Manufacturing Without Sacrificing Performance.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Meeting Pharmacopeia Regulations & Controlling the Risk of Contamination in Pharmaceutical Waters, Upcoming Webinar Hosted by Xtalks


Effective analytics can help pharmaceutical companies meet global pharmacopeia requirements and ensure the most effective process control to meet their compliance needs.

This webinar will cover key analytical requirements and regulations to ensure pharmacopeia compliance of pharmaceutical waters. The featured speaker will also discuss methods for implementing real-time measurement to improve process control to achieve compliance with those regulatory requirements.

The panelist will start with a background of the US Pharmacopeia (USP) and the updated process for USP, including supplements and major revisions. He will also talk about the global panel of experts that make up the USP. This will lead into a discussion on how the USP is harmonized with other global pharmacopeias, including European Pharmacopeia (EP), Japanese Pharmacopeia (JP), Chinese Pharmacopeia (ChP) and Indian Pharmacopeia (IP).

The speaker will then move into three specific analytics for pharmaceutical waters and the related measurement to help ensure pharmacopeia compliance of pharmaceutical waters. Those measurements are conductivity, microbial contamination and TOC. For measuring conductivity, the speakers will discuss the benefits of in-line measurement of conductivity, the importance of temperature compensation (USP1644) and non-temperature compensated (USP 645) measurement, and how participants can achieve both efficiently.

In TOC monitoring, the benefits of oxidation/conductivity methods to help ensure a compliant water system will be discussed. The speaker will then discuss the trend towards implementing online bioburden detection as a method of process control in parallel to plate counting. In shifting to online water bioburden analysis (OWBA), many pharmaceutical companies have questions about the regulatory perspective. The panelist will discuss the regulatory perspective on this topic, including providing an overview of how different workgroups in the industry are engaging on this topic. He will conclude with a summary of how effective analytics can help pharmaceutical companies meet global pharmacopeia requirements and ensure the most effective process control to meet their compliance needs.

Join Jim Cannon, Head of OEM and Markets, Mettler-Toledo Thornton, in a live webinar on Monday, December 14, 2020 at 10am EST (3pm GMT/UK).

For more information, or to register for this event, visit Meeting Pharmacopeia Regulations & Controlling the Risk of Contamination in Pharmaceutical Waters.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

CYA Smart Alliance Builds Strength in Numbers


CYA Smart Alliance Builds Strength in Numbers

As the alliance gains momentum, the movement to bring sanity back to pool and water care has shifted from a topic of conversation to actionable change

Leading pool professionals from across the industry have continued to join the CYA Smart Alliance to help meet customers’ demands for better, sustainable, and consistent water care. As the alliance gains momentum, the movement to bring sanity back to pool and spa water care has shifted from a topic of conversation to actionable change. Pool and spa professionals’ can join the CYA Smart Alliance at cyasmart.org.

“We are happy to welcome the fast growing number of members and support them as they promote better water care,” states Steve Berens, CEO of Clear Comfort, a founding member of the CYA Smart Alliance. “The more industry professionals that commit to being CYA Smart™ the quicker we can provide simplified water care to pool and spa owners.”

By joining, CYA Smart Alliance members dedicate their company’s water care methods to significantly reduce cyanuric acid overstabilization and the problems that it brings. Addressing the ongoing cycle of chemical overtreatment leading to water and chemical waste from CYA is long overdue. The CYA Smart Alliance aims to stop the cycle, give pool and spa owners back control of their water and deliver a swimming experience focused on sustainability and consistency.

“The support and commitment the CYA Smart Alliance has experienced so far not only gives a promising outlook for the pool industry but for pool and spa owners as well,” says Zdenek Kratky, CMO at Sigura. “By coming together with one common goal, members are able to help each other and work collaboratively which has been missing from the industry.”

The CYA Smart Alliance continues to welcome new members from the pool industry to propel the movement further forward. As a new member, Kevin Boyer, COO of Poolsure (Greater Texas) said, “We are thrilled to partner with a group of like minded companies to continue the work of smart pool chemistry education in support of our core mission of promoting safe water and healthy swimming across our service areas.”

Zac Nicklas from The Pool Boys (League City, Texas) adds, “The number one issue we fight with chlorine pools is high CYA, so it was a natural fit when we found the CYA Smart Alliance. Using less chemicals while creating a better swimming experience is the smart choice for healthier water and a happy customer.”

The more growth the alliance gains, the quicker positive change will happen for the pool industry and for consumers wanting healthier water right now. “The topic of cyanuric acid use in pool and spa water has been around for too long without action. We are very excited to join the CYA Smart Alliance and begin taking steps to remedy this issue,” Don Hummel, Owner of WaterworX Pool and Spa (Camarillo, California) stated.

The CYA Smart Alliance is proud to welcome its newest members including the following industry leaders:

1. Poolsure (Greater Texas)

2. The Pool Boys (League City, Texas)

3. WaterworX (Camarillo, California)

4. Green Gecko Pools and Spas, LLC (Chicago, Illinois)

5. G2 Aquatics, Inc. (Naples, Florida)

6. A-Quality Pools (North Richland Hills, Texas)

7. Atlantic Aquatech (Ocean City, Maryland)

8. Fluid Design Concepts, LLC (Waynesboro, Virginia)

9. E-Konomy Pool Service & Supplies (Tucson, Arizona)

10. The Pool Guy (Broussard, Louisiana)

To join the CYA Smart Alliance and get involved, please visit cyasmart.org.

About the CYA Smart Alliance

The CYA Smart Alliance is industry leaders coming together to bring sanity back to pool and spa care. They are taking action to improve water care and swimming. Members of the CYA Smart Alliance are actively committing to simpler pool and spa care, safe and healthy water, and sustainability by saving water. They are choosing a smarter, easier, way forward. Coupling Smart Oxidation™ with Smart CYA™ in pools and spas is the beginning of the journey to a better industry.

About Clear Comfort

Clear Comfort manufactures and sells non-chlorine pool and spa water disinfection systems. Clear Comfort’s patented hydroxyl-based advanced oxidation (AOP) technology provides the best swimming experience available with proven, effective and non-toxic treatment. With headquarters and manufacturing based in Colorado, Clear Comfort customers receive a sustainable, “Made in the USA” product. Clear Comfort is a proud Impact Driven™ company delivering healthy, ethical and sustainable solutions to the market. For more information about Clear Comfort, please visit clearcomfort.com.

About Sigura™

Headquartered in Alpharetta, GA, Sigura is a leading provider of innovative water treatment solutions. The company maintains six production facilities throughout North America, South America, Europe and Africa, with 1,200 employees globally, located in all major regions. It features top consumer brands in the residential pool care market and strong positions in high-growth Industrial & Municipal water markets. Key brands include HTH®, Pulsar®, poolife®, GLB®, Applied Biochemists®, Leisure Time®, Baquacil®, BaquaSpa®, Constant Chlor®, Hypocal®, and more. To learn more about Sigura visit http://www.sigurawater.com

Share article on social media or email:

Stratus Appoints David N. Hruda Chief Compliance Officer


Stratus, the nation’s leading provider of in-home neurodiagnostic testing services, today announced the appointment of David N. Hruda as chief compliance officer.

As chief compliance officer, Hruda will be responsible for overseeing compliance, risk, and ethics within the organization, and ensuring adherence with laws and regulatory requirements. He will focus on developing, implementing, and overseeing compliance policies and procedures, as well as programs to prevent, detect, and take appropriate remedial measures to address any non-compliance. Hruda will report directly to Charlie Alvarez, chief executive officer and the company’s board of directors.

Hruda joins Status with more than 20 years of legal, compliance, and business experience. Prior to joining Stratus, he served as Vice President of Legal and Compliance for BioSerenity, Inc, a global company that provides services in sleep, electroencephalogram (EEG), and cardiac diagnostics. Hruda was responsible for providing counsel on compliance, risk management, healthcare regulations, and data privacy.

“Stratus is commited to providing safe and quality care to our physicians and patients, as well as to conducting our business with the highest level of integrity and compliance,” said Charlie Alvarez, chief executive officer of Stratus. “David’s qualifications and his proven track record leading regulatory and compliance in the health care industry make him the perfect fit for the company. His addition to our leadership team will help us further our commitment to conduct business ethically and in compliance with the laws and regulations that govern our business and industry.”

Prior to BioSerenity, Hruda was senior attorney at the law firm of Alexander & Cleaver. In this role, he advised clients on HIPAA, HITECH and the design and implementation of compliance programs. Hruda has also served as chief compliance officer and general counsel for Watermark Medical Holdings, Inc. He was part of the company startup, advising leadership on compliance, risk management, and healthcare regulations. Hruda’s additional start-up company experience includes time as the chief compliance officer at PDSHeart, Inc., which was acquired by CardioNet, Inc, now known as Biotel.

Hruda earned a Bachelor’s Degree in Social Sciences from the University of Maryland. He earned his JD from the University of Baltimore School of Law.

For more information on Stratus, visit http://www.stratusneuro.com.

About Stratus

Stratus is the nation’s leading provider of ambulatory in-home video EEG and has served more than 60,000 patients across the U.S. The company offers technology, services, and proprietary software solutions to help neurologists accurately and quickly diagnose their patients with epilepsy and other seizure-like disorders. Stratus also provides mobile cardiac telemetry to support the diagnostic testing needs of the neurology community. Additionally, the company’s R&D division holds the world’s largest database of de-identified EEG recordings and is applying machine learning to improve the overall quality and efficiency of EEG testing. To learn more, visit http://www.stratusneuro.com.

Share article on social media or email:

Maximizing Biorepositories for Research & Drug Discovery, Upcoming Webinar Hosted by Xtalks


Maximizing utility and sustainability are critical for the long-term success of biorepositories and biobanks.

Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and challenges facing biorepositories and biobanks around the world seeking to maximize their resources for research and drug discovery. Whether the repository contains a small collection of samples or is a large-scale national or international repository, biobanking will continue to play a key role in accelerating the discovery and development of new drugs, as these efforts require access to a larger array of biological samples. At the same time, biobanks face a variety of challenges in meeting the different interests and unique needs of their collaborators and partners in order to support a growing number of research studies. Maximizing utility and sustainability are critical for the long-term success of biorepositories and biobanks.

This webinar will explore the enormous innovative potential for biobanks and biorepositories to support translational research using a variety of bio-sample types (tissue samples, tumor cells, DNA, RNA, blood samples) collected from population-based and/or disease-specific groups of individuals.

Join Professor Stephen Sawcer, University of Cambridge, Dept. of Clinical Neurosciences; Samantha Hutten, Staff Scientist, Michael J Fox Foundation for Parkinson’s Disease Research (MJFF); Gordon R. Bernard, MD, Executive Vice President for Research and Chief Research Officer, Vanderbilt University Medical Center (VUMC), and David Kavanagh, PhD, Director of Clinical Partnerships, Genuity Science in a live webinar on Tuesday, December 15, 2020 at 10am EST (3pm GMT/UK).

For more information, or to register for this event, visit Maximizing Biorepositories for Research & Drug Discovery.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Press Release News Wire Service